In the case of breast cancer, PTPRO promoter methylation is a prognostic factor for HER2-positive patients and suppresses ERBB2-driven breast cancer growth by promoting ERBB2 dephosphorylation and endocytotic degradation [9, 16]. This evidence concerns the gene ERBB2 and breast carcinoma.